Figure S3 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma

2026 Open access

Read full text
Authors: W. Frank Lenoir, Michael R. McKeown, Giulia Giorgetti, Marek J. Kobylarz, Tamara D. Hopkins, Wayne L. Glore, Michelle G. Shum, Yaretzi Calderón, Jessica Encinas, Luis A. Carvajal, Kameron R. Mori, Jun Li
+11 more Hua Gao, Yupeng Zheng, Zhihua Ma, Nikolaus D. Obholzer, Minyun Zhou, Benjamin W. Trotter, Christopher J. Dinsmore, Nikhil C. Munshi, Charles Y. Lin, Mariateresa Fulciniti, Peter B. Rahl
DOI: 10.1158/0008-5472.31345661
Cited by: 0

Abstract

KB528 treatment leads to changes in the acetylation of transcription factors and chromatin in MM cells and results in changes to the IRF4 signature similar to IRF4 knockdown.

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Histone Deacetylase Inhibitors Research

Publication details

Publication date
16 February 2026
Language
EN